drugset / Press release
Emergent BioSolutions Presents Positive Interim Phase 2 Data Evaluating Otlertuzumab (TRU-016) in Combination with Bendamustine in People with Relapsed Chronic Lymphocytic Leukemia
2013-12-09 · Emergent BioSolutions · original emergentbiosolutions.com ↗
120913 - EBS Presents Ph2 Data Otlertuzumab Bendamustine in Relapsed CLL FINAL.pdf 203.6 KB
The release as fetched from its publisher. emergentbiosolutions.com ↗